Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLLJacob D. Soumerai, Deborah M. Stephens, Ryan Jacobs et al.|Blood Advances|2024Cited by 19
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N. Shah, Jennifer R. Brown, Michael Wang et al.|Haematologica|2024Cited by 12
Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patientsYun Kyoung Tiger, Venkata Preetam Sandeep Kaduluri, Taylor Kujawa et al.|Blood|2025Cited by 0